Skip to main content

Table 1 Baseline characteristics of the patients receiving educational materials and SMS texting (mHealth)

From: Strengthening therapeutic adherence and pharmacovigilance to antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth

Characteristics Non-contacted group
n = 450
Contacted group
n = 1062
Total
N = 1512
Age in yearsa
 16–25 104 (25.11) 240 (22.60) 344 (22.75)
 26–35 129 (28.67) 267 (25.14) 396 (26.19)
 36–45 97 (21.56) 260 (24.48) 357 (23.61)
 46–83 120 (26.67) 295 (27.78) 415 (27.45)
Gender (% male)a 285 (63.33) 641 (60.36) 926 (61.24)
Ethnicity (%)a    
 White 7 (1.56) 37 (3.48) 44 (2.91)
 Pardo (mixed) 365 (81.11) 852 (80.23) 1217 (80.49)
 Indigenous 1 (0.22) 0 (0.00) 1 (0.07)
 Black 11 (2.44) 40 (3.77) 51 (3.37)
 Yellow 3 (0.67) 9 (0.85) 12 (0.79)
 Unknown 63 (14.00) 124 (11.68) 187 (12.37)
Type of malariaa    
 P. Vivax 444 (98.67) 1,046 (98.49) 1490 (98.54)
 P. Falciparum 5 (1.11) 8 (0.75) 13 (0.96)
 Mixed infection/other 1 (0.22) 8 (0.75) 9 (0.60)
Treatment regimena    
 Long standard regimen CQ + PQb 19 (4.22) 23 (2.17) 42 (2.78)
 Short standard regimen QC + PQc 425 (94.44) 1025 (96.52) 1450 (95.90)
 Combined therapy AT + PQd 5 (1.11) 7 (0.66) 12 (0.79)
 Mixed malaria schemef 1 (0.22) 7 (0.66) 8 (0.53)
  1. CQ: chloroquine; PQ: primaquine; AT: artemisin; a No statistically significant difference between contacted and uncontacted groups (P ≥ 0.05); b Long standard regimen: Chloroquine 25 mg / kg weight divided in 3 days (1500 mg adult dose) + Primaquine 0.25 mg / kg weight for 14 days (15 mg per day); c Short standard regimen: chloroquine for three days (10 mg / kg on day 1 and 7.5 mg / kg on days 2 and 3) + Primaquine 0.50 mg / kg weight for 7 days (30 mg per day); d Combined therapy based on Artemisin + Primaquine (single dose) 3 days; f Mixed malaria scheme: Artemisinin + Primaquine 2 tablet of 15 mg (single daily dose) for 7 days (double dose)